Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)
Protalix BioTherapeutics (PLX) posted quarterly Short term Debt of $20.4 million for Q2 2024, little changed quarter-over-quarter from $20.4 million in Q1 2024.
Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024) Analysis & Trends
Protalix BioTherapeutics' Short term Debt history runs 7 years deep, the most recent figure standing at $20.4 million for Q2 2024.
- In Q2 2024, Short term Debt changed N/A year-over-year to $20.4 million; the TTM figure through Jun 2024 stood at $20.4 million (changed N/A YoY), while the FY2023 annual figure was $20.3 million, changed N/A from the prior year.
- Short term Debt for Q2 2024 stood at $20.4 million, roughly flat from $20.4 million in the prior quarter.
- The five-year high for Short term Debt was $56.4 million in Q2 2021, with the low at $3.2 million in Q3 2021.
- The 4-year median for Short term Debt is $20.4 million (2024), against an average of $31.3 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - |
| 10 | Protalix BioTherapeutics | 193.97 Mn | 153.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 20.42 Mn |
| Mar 31, 2024 | 20.42 Mn |
| Dec 31, 2023 | 20.25 Mn |
| Sep 30, 2023 | 20.19 Mn |
| Sep 30, 2021 | 3.24 Mn |
| Jun 30, 2021 | 56.36 Mn |
| Mar 31, 2021 | 55.37 Mn |
| Dec 31, 2020 | 54.43 Mn |
| Mar 31, 2018 | 5.93 Mn |
| Dec 31, 2017 | 5.92 Mn |
| Sep 30, 2017 | 5.91 Mn |
| Dec 31, 2016 | 53.87 Mn |